Terms: = Prostate cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
19 results:
1. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.
Yuan T; Zhang S; He S; Ma Y; Chen J; Gu J
Sci Rep; 2023 Sep; 13(1):15916. PubMed ID: 37741901
[TBL] [Abstract] [Full Text] [Related]
2. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
3. TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors.
Bacon JVW; Giannatempo P; Cataldo G; Fazli L; Saxena N; Ozgun G; Soleimani M; Chi K; Nichols C; Necchi A; Wyatt AW; Kollmannsberger CK; Nappi L
Oncologist; 2022 Nov; 27(11):e912-e915. PubMed ID: 36166584
[TBL] [Abstract] [Full Text] [Related]
4. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes.
Karpova Y; Johnson SJ; Bordet G; Guo D; Ghatak A; Markov DA; Tulin AV
Biomed Pharmacother; 2022 Sep; 153():113504. PubMed ID: 36076593
[TBL] [Abstract] [Full Text] [Related]
5. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
[TBL] [Abstract] [Full Text] [Related]
6. Metastatic pancreatic cancer: Mechanisms and detection (Review).
Chen X; Liu F; Xue Q; Weng X; Xu F
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498718
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal cancer.
Rajamäki K; Taira A; Katainen R; Välimäki N; Kuosmanen A; Plaketti RM; Seppälä TT; Ahtiainen M; Wirta EV; Vartiainen E; Sulo P; Ravantti J; Lehtipuro S; Granberg KJ; Nykter M; Tanskanen T; Ristimäki A; Koskensalo S; Renkonen-Sinisalo L; Lepistö A; Böhm J; Taipale J; Mecklin JP; Aavikko M; Palin K; Aaltonen LA
Gastroenterology; 2021 Aug; 161(2):592-607. PubMed ID: 33930428
[TBL] [Abstract] [Full Text] [Related]
8. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract] [Full Text] [Related]
9. Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis.
Parra-Medina R; López-Kleine L; Ramírez-Clavijo S; Payán-Gómez C
Sci Rep; 2020 Jul; 10(1):12345. PubMed ID: 32704070
[TBL] [Abstract] [Full Text] [Related]
10. HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
Kogler M; Tortola L; Negri GL; Leopoldi A; El-Naggar AM; Mereiter S; Gomez-Diaz C; Nitsch R; Tortora D; Kavirayani AM; Gapp BV; Rao S; Uribesalgo I; Hoffmann D; Cikes D; Novatchkova M; Williams DA; Trent JM; Ikeda F; Daugaard M; Hagelkruys A; Sorensen PH; Penninger JM
Cancer Res; 2020 Jul; 80(14):3009-3022. PubMed ID: 32366477
[TBL] [Abstract] [Full Text] [Related]
11. [Molecular Pathogenesis of Colorectal cancer].
Král J; Slyšková J; Vodička P; Špičák J
Klin Onkol; 2016; 29(6):419-427. PubMed ID: 27951718
[TBL] [Abstract] [Full Text] [Related]
12. Transcriptome and Proteome Analyses of TNFAIP8 Knockdown cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression.
Day TF; Mewani RR; Starr J; Li X; Chakravarty D; Ressom H; Zou X; Eidelman O; Pollard HB; Srivastava M; Kasid UN
Methods Mol Biol; 2017; 1513():83-100. PubMed ID: 27807832
[TBL] [Abstract] [Full Text] [Related]
13. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
[TBL] [Abstract] [Full Text] [Related]
14. Personalised cancer medicine.
Jackson SE; Chester JD
Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
[TBL] [Abstract] [Full Text] [Related]
15. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.
Lotan TL; Gumuskaya B; Rahimi H; Hicks JL; Iwata T; Robinson BD; Epstein JI; De Marzo AM
Mod Pathol; 2013 Apr; 26(4):587-603. PubMed ID: 23222491
[TBL] [Abstract] [Full Text] [Related]
16. Circulating tumor cells in lung cancer.
Young R; Pailler E; Billiot F; Drusch F; Barthelemy A; Oulhen M; Besse B; Soria JC; Farace F; Vielh P
Acta Cytol; 2012; 56(6):655-60. PubMed ID: 23207444
[TBL] [Abstract] [Full Text] [Related]
17. Tumor markers in clinical practice: a review focusing on common solid cancers.
Duffy MJ
Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
[TBL] [Abstract] [Full Text] [Related]
18. cancer immunology--analysis of host and tumor factors for personalized medicine.
Ogino S; Galon J; Fuchs CS; Dranoff G
Nat Rev Clin Oncol; 2011 Aug; 8(12):711-9. PubMed ID: 21826083
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis.
Dammann R; Schagdarsurengin U; Strunnikova M; Rastetter M; Seidel C; Liu L; Tommasi S; Pfeifer GP
Histol Histopathol; 2003 Apr; 18(2):665-77. PubMed ID: 12647816
[TBL] [Abstract] [Full Text] [Related]
